Related Experiment Video
Updated: Mar 22, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.2K
Biomarkers associated with checkpoint inhibitors
G Manson1, J Norwood1, A Marabelle2
1Department of Hematology, CHU Rennes, Rennes.
Summary
Checkpoint inhibitors (CPI) show cancer treatment efficacy but cause side effects and varied responses. Biomarkers predicting CPI effectiveness and immune-related adverse events (irAE) are crucial for patient selection.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Checkpoint inhibitors (CPI), including anti-CTLA4 and anti-PD1/PD-L1 antibodies, are effective cancer treatments.
- Patient response to CPI varies, with only subgroups benefiting.
- CPI therapy can lead to severe immune-related adverse events (irAE).
Purpose of the Study:
- To review key biomarkers associated with CPI efficacy.
- To identify biomarkers linked to CPI-induced toxicity (irAE).
- To guide patient selection for CPI therapy.
Main Methods:
- Literature review of studies on CPI biomarkers.
- Analysis of pharmacodynamic and clinical benefit markers.
- Assessment of markers correlating with irAE development.
Main Results:
- Several biomarkers are associated with CPI efficacy and clinical outcomes.
- Specific biomarkers correlate with the risk and severity of irAE.
- Biomarker profiles can differ for efficacy and toxicity.
Conclusions:
- Biomarkers are essential for predicting CPI response and toxicity.
- Identifying predictive biomarkers can optimize patient selection for CPI therapy.
- Further research into biomarkers may improve CPI treatment strategies.
